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Autoimmunity, infectious diseases and cancer affect women and men differently. Because 
they tend to develop more vigorous adaptive immune responses than men, women are 
less susceptible to some infectious diseases but also at higher risk of autoimmunity. The 
regulation of immune responses by sex-dependent factors probably involves several 
non-redundant mechanisms. A privileged area of study, however, concerns the role of sex 
steroid hormones in the biology of innate immune cells, especially dendritic cells (DCs). 
In recent years, our understanding of the lineage origin of DC populations has expanded, 
and the lineage-committing transcription factors shaping peripheral DC subsets have 
been identified. Both progenitor cells and mature DC subsets express estrogen receptors 
(ERs), which are ligand-dependent transcription factors. This suggests that estrogens 
may contribute to the reported sex differences in immunity by regulating DC biology. 
Here, we review the recent literature and highlight evidence that estrogen-dependent 
activation of ERα regulates the development or the functional responses of particular DC 
subsets. The in vitro model of GM-CSF-induced DC differentiation shows that CD11c+ 
CD11bint Ly6cneg cells depend on ERα activation by estrogen for their development, and 
for the acquisition of competence to activate naive CD4+ T lymphocytes and mount a 
robust pro-inflammatory cytokine response to CD40 stimulation. In this model, estrogen 
signaling in conjunction with GM-CSF is necessary to promote early interferon regu-
latory factor (Irf)-4 expression in macrophage-DC progenitors and their subsequent 
differentiation into IRF-4hi CD11c+ CD11bint Ly6cneg cells, closely related to the cDC2 
subset. The Flt3L-induced model of DC differentiation in turn shows that ERα signaling 
promotes the development of conventional DC (cDC) and plasmacytoid DC (pDC) with 
higher capability of pro-inflammatory cytokine production in response to TLR stimulation. 
Likewise, cell-intrinsic ER signaling positively regulates the TLR-driven production of type 
I interferons (IFNs) in mouse pDCs in vivo. This effect of estrogens likely contributes to 
the greater proficiency of women’s pDCs than men’s as regards the production of type I 
IFNs elicited by TLR7 ligands. In summary, evidence is emerging in support of the notion 
that estrogen signaling regulates important aspects of cDC and pDC development and/
or effector functions, in both mice and humans.
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iNTRODUCTiON
The pro-inflammatory role of estrogens, particularly through 
their actions on the innate immune system, has been proposed 
to contribute to the higher immune responses that develop in 
women (1, 2). Estrogen mediates their effects through two recep-
tors, estrogen receptors (ERs) ERα and ERβ, which are members 
of the nuclear receptor super family (3). ERα and ERβ function in 
the nucleus as transcription factors in a ligand-dependent man-
ner. Many studies have shown that mature cells both from the 
innate and the adaptive immune system express ERs, particularly 
ERα in mouse (4–10) suggesting that estrogens could regulate 
their effector functions. Estrogens could also directly act, through 
their receptors, on progenitor cells to influence the development 
of myeloid and lymphoid cells (11–17).
Dendritic cells (DCs) are professional antigen-presenting cells 
that bridge innate and adaptive immunity. They are essential for the 
activation of naive T cells specific to self or non-self protein anti-
gens and for their subsequent differentiation into effector T (Teff) 
cells through the secretion of specific cytokines (18). Ontogeny 
and global gene expression studies indicate that DCs form a sepa-
rate lineage of mononuclear phagocytes or mononuclear-derived 
cells, notably on the basis of their continual replenishment from 
common DC precursors that are distinct from the precursors of 
monocytes and macrophages (19). DCs are subdivided into three 
main subtypes: conventional DCs (cDCs), monocyte-derived DCs 
and plasmacytoid DCs (pDCs) (19). While cDCs are specialized 
in antigen processing and presentation, thereby converting naive 
T cells into effector CD4+ and CD8+ Teff cells, blood monocytes 
can be rapidly mobilized from the circulation and differentiate 
into monocyte-derived cells (MCs) with distinct functions such 
as local reactivation of Teff cells, and superior inflammatory and 
chemokine production relative to cDCs (18). By contrast, pDCs 
produce massive amounts of type I interferons (IFNs) in response 
to viral infections (20).
This review surveys the state of the knowledge regarding estro-
gen-dependent regulation of DC biology and revisits previously 
published experiments in light of recent advances in the DC field 
(18, 19, 21). We will focus on key experimental studies supporting 
a direct regulatory role of sex hormone estrogens vis-à-vis cDCs 
and pDCs, which hinges on the ligand-dependent activation of 
their nuclear receptor, ERα (summarized in Table 1).
eR eXPReSSiON iN HeMATOPOieTiC 
CeLLS
Estrogen receptors are ligand-inducible transcription factors 
whose activity is regulated by endogenous estrogens naturally 
produced over the estrus cycle or during pregnancy. The main 
endogenous estrogens are estrone (E1), 17β-estradiol (E2), estriol 
(E3) and estetrol (E4), with E2 as the predominant and most bio-
logically active of the four. In humans, E3 and E4 are selectively 
produced during pregnancy, by the placenta or by the fetal liver, 
respectively. ER activities can be modulated also by exogenous 
ligands, such as synthetic, non-steroidal, non-hormonal ago-
nist, and antagonist ligands known as selective ER modulators 
(SERMs) (30). SERMs such as tamoxifen and raloxifen are in 
current clinical use for the treatment of breast cancer and osteo-
porosis, respectively. It is, therefore, important to understand 
how such molecules, through ER signaling, may interfere with the 
development and/or function of immune cells. Despite a growing 
body of evidence that ER-dependent mechanisms influence both 
the development and the function of innate immune cells, few 
studies have sought to determine the relative expression of ER 
isotypes in different steady-state populations of immune cells. 
Estrogens exert their effects through two known nuclear recep-
tor family members: ERα, which is encoded by ESR1 on human 
chromosome 6, and ERβ, which is encoded by the ESR2 locus on 
chromosome 14 (30).
Estrogen receptors are widely expressed in most tissues of both 
women and men (31). They have also been identified in many 
different immune cell types including hematopoietic precursors 
(32). Both ER are expressed in CD34+ human hematopoietic 
progenitor cells (HPCs) found in the bone marrow, but not in 
HPCs from cord blood (33–36). These findings indicate that hor-
mone-receptor expression is highly regulated in hematopoietic 
precursors during development. The absence of ER expression in 
HPCs from cord-blood may protect the fetus from high hormone 
levels that suppress maternal lymphopoiesis (33) while promot-
ing hematopoietic stem cell (HSC) self-renewal and myelopoiesis 
(35). Indeed, E2 signaling through ERα was recently reported 
to promote the cycling of HSCs and multipotent progenitors, 
thereby supporting the increased demand for erythropoiesis 
during pregnancy (35).
In mature human cells, monocyte-derived DCs express ESR1 
transcripts and low levels of ESR2 mRNA (37, 38). ESR1 expres-
sion was comparable between CD4+, CD8+ T cells, and natural 
killer cells, which also expressed ESR2 although at lower levels. B 
lymphocytes expressed the highest levels of ESR1 mRNA relative 
to other leukocytes. Of note, B cells and pDCs displayed the high-
est levels of ESR2 mRNA in comparison with any other cell type 
examined (38). As previously reported (39), expression levels of 
both ER isotypes were low in blood monocytes, despite evidence 
in mouse that E2 promoted the TLR4-mediated production of 
pro-inflammatory cytokines by peritoneal monocyte and mac-
rophage cells, through cell-intrinsic ERα-signaling in vivo (7, 8) 
(Table 1).
In mice, Esr1, but not Esr2, is expressed in bone marrow 
progenitor cells, including the common lymphoid progenitor 
(CLP) and myeloid progenitor (MP) compartments (15). Most of 
the mature immune cells likewise express Esr1, with so far little 
evidence for Esr2-dependent regulation. A notable exception is 
microglia, the brain-resident macrophages, where TLR-mediated 
response can be differentially regulated through ERα- or ERβ-
dependent mechanisms (40, 41). Murine splenic cDCs and 
pDCs, as well as bone marrow-derived DCs (BMDCs), also 
express Esr1, but only negligible levels of Esr2 (32). However, ER 
expression can be modulated by the tissue microenvironment or 
by the activation status of the cells, as DCs infiltrating the brain 
during experimental autoimmune encephalomyelitis (EAE) 
express ERβ, unlike splenic DCs (42). Moreover, evidence exists 
that regulatory cytokines, such as IL-27, can induce a dramatic 
increase in Esr1 gene expression in cDCs, although the functional 
TABLe 1 | effect of estrogen receptor (eR)α signaling on dendritic cells (DCs) and monocyte-derived cells in mouse models.
Cell population Models effect of eRα signaling
GM-CSF-induced 
conventional DCs 
(cDCs)
In vitro ERα-deficient mice  (a) Estrogen deficiency or ER-blockade with ICI182,780 in vitro inhibits the development of CD11c+ CD11bint 
Ly6C− Csf-2-induced-DC (12, 22, 23); partial inhibition of DC development with first generation of  
ERα-mutant mice still expressing a truncated form of ERα lacking AF-1 domain (12)
 (b) First demonstration of the unique role of ERα, but not ERβ, in the development of Csf-2-induced-DC; 
promotion of the maturation and pro-inflammatory cytokine production in response to CD40 and TLR9 
stimulation (16)
 (c) E2 acts on macrophage-DC progenitor (MDP) to promote the development and the effector functions of 
CD11c+MHCII+ cells through the upregulation of interferon regulatory factor (IRF)-4 (15, 17, 24); ERα AF-1 
is partially dispensable for Csf-2-induced GM-DC development (24)
FLT3L-induced cDCs In vitro ERα-deficient mice  (a) E2 inhibits the development of plasmacytoid DCs (pDCs) and cDCs in Flt3L-driven BM cultures, through 
direct action on MDP, functional impact of E2/ERα not evaluated in this study (15)
 (b) E2/ERα enhances the maturation and pro-inflammatory cytokine production (IL-6, IL-12) in response to 
dual signaling through CD40 and TLR4 or TLR9 stimulation; normal cDC development in the absence of 
ERα (24)
FLT3L-induced pDCs In vitro ERα-deficient mice E2/ERα signaling blunts the development of pDCs in vitro, but enhances the expression of maturation 
markers and their effector functions in response to TLR9 in vitro; ERα-AF-1−/− pDCs in vivo exhibited reduced 
production of interferon (IFN)-α in response to TLR7 ligand (24)
pDCs (bone marrow) In vivo CD11c-Cre x Esr1flox/flox 
and Tie2-Cre × Esr1flox/flox  
deleter models
 (a) Promotion of type I IFNs and pro-inflammatory cytokine production in response to TLR7 and TLR9 ligand 
(10, 25)
 (b) Enhanced type I IFN production in female bone marrow pDCs stimulated through TLR7 associated with 
upregulation of Irf5, but not Irf7 expression (25)
Monocyte/
macrophages
Ex vivo ERα-deficient mice 
peritoneal macrophages (PM); 
testicular macrophages; bone 
marrow-derived macrophages; 
wound macrophages
Pro-inflammatory effects:
 (a) E2 supplementation in Ovx mice increases the LPS-mediated production of pro-inflammatory cytokines 
[IL-1β, IL-6, intracellular nitric oxide synthase (iNOS)] by PM through inhibition of phosphoinositide 3-kinase 
activity; no effect on TLR4 expression (7)
 (b) ERα in testicular macrophages promotes CD69, TAM receptor expression, tumor necrosis factor  
(TNF)-α production macrophage activation, and engulfment of Leidig cells (26)
Anti-inflammatory effects, tissue repair:
 (c) ERα-deficient PM exposed ex vivo to LPS or Mycobacterium avium exhibited enhanced production of 
TNF-α (27)
 (d) ERα promotes alternative macrophage activation and tissue repair in cutaneous wounds healing (28)
Monocyte/
macrophages
LysM-Cre  × Esr1flox/flox deleter 
model PM; bone marrow-
derived macrophages
 (a) Related to Ref. (7), first demonstration that cell-intrinsic ERα-signaling in vivo in PM positively regulates the 
TLR4-dependent production of pro-inflammatory cytokines (IL-1β, IL-6, and iNOS) (8)
 (b) ERα is necessary for full phagocytic capacity of PM; ERα directly regulates transglutaminase 2 expression; 
ERα is critical for the maintenance of macrophage metabolism (29)
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consequences of this upregulation are presently unknown (43). 
ERα appears thus to be the most prominent ER in the human and 
murine dendritic cell lineages, even though human pDCs express 
both ESR1 and ESR2 transcripts (38).
MeCHANiSMS OF eR SiGNALiNG
The ERα and ERβ paralogs are conserved across vertebrate 
lineages (44). The proteins share five functional and structural 
domains: two transcriptional activation function domains, AF-1 
(A/B domain) and AF-2 (F domain); a DNA-binding domain 
(DBD; C domain); a hinge domain (D); and a ligand-binding 
domain (LBD; E/F domain) (45–47).
Following interaction with its estrogen ligand, an ER can 
regulate cellular function through either of two different mecha-
nisms: the nuclear genomic mechanism, implying direct or 
indirect binding of the receptor to transcription control regions 
of targeted genes, and the non-genomic mechanism, initiated 
by receptors at the cell membrane, which signal through kinase 
pathways (47).
Occupation of the ligand cavity of the LBD results in con-
formational changes in the receptor allowing interaction with 
coactivators, if the ligand is an agonist, or preventing such interac-
tions, if the ligand is an antagonist (48). Transcriptional responses 
to estrogens were initially recognized to depend on specific 
interaction of homo/heterodimeric ERs with estrogen-response 
elements (EREs, GGTCANNNTGACC) found in the promoters 
of target genes. In addition to this “classical” pathway, a “tethered” 
signaling pathway has been described in which ligand-activated 
ERs can interact with other transcription factor complexes and 
bind to non-ERE sequences. ERs can thus regulate a number of 
key transcriptional pathways including those of NF-κB, AP-1, 
Sp-1, and C/EBPβ (30). Of note, the AP-1 and Sp-1 transcription 
factor family members are ubiquitously expressed and are known 
to regulate the expression of several genes important for immune 
cell development and function (49, 50).
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In cancer cells, it has been shown that estrogen-bound ERα 
can regulate gene expression through its direct or indirect recruit-
ment to target gene promoters, or through its binding to distant 
regulatory elements or enhancers. ERα molecules can associate 
with other cofactors such as GATA-3, P2A-g, and FOXA1 to the 
establishment of chromatin loops, bringing distal ERα-bound 
elements to the vicinity of the transcription start site in target 
genes (51, 52). Once bound, ERα associates with coactivator pro-
teins displaying chromatin-modification properties potentiating 
the recruitment of RNA polymerase II and chromatin remodeling 
enzymes, such as histone modifying enzymes (HATs, HDACs, 
and HMTs) (53, 54). It is unknown, however, whether such 
mechanisms occur in non-reproductive tissues, such as immune 
cells, in which ER expression is 100-fold lower than in breast 
cancer cells. Moreover, limited information exists regarding the 
expression of ER at the protein level in immune cell subsets, as 
control experiments using appropriate knockout cells are often 
missing in many experimental settings. However, ER protein lev-
els do not necessarily correlate with mRNA expression, as shown 
for ER- cancer cells, owing to the coupling of ER cytoplasmic 
signaling cascades and target gene transcription with rapid ER 
proteolysis effected by the ubiquitin-proteasome system (55).
Full ligand-dependent ERα activation entails interactions 
between the AF domains, but the AF-1 and AF-2 transactiva-
tion domains can independently activate transcription in a 
promoter- and cell type-specific manner (46, 56, 57). The relative 
contribution of AF-1 and AF-2 in ERα activity may depend upon 
the differentiation stage of the cells (58) or the tissue examined 
(59). Mice lacking either AF-1 (ERαAF-10) or AF-2 (ERαAF-20) 
have been recently generated (60–62). Using these animal mod-
els, it has been shown that ERαAF-1 was required neither for the 
E2-dependent vasculoprotective effects (60) nor for osteoporosis 
prevention (62). AF1 was, however, necessary for breast cancer 
cell proliferation (63) and uterine growth (60). Unlike AF-1, AF-2 
was required for all E2-mediated actions with the exception of the 
acceleration of endothelial healing (61, 62).
Apart from the “genomic/nuclear” actions that classically rely 
on AF-1 and/or AF-2 activation, E2 modulates also the activation 
of several kinases [MAPK, phosphoinositide 3-kinase (PI3K) or 
PKC], phosphatases, and adenylyl cyclase as well as changes in 
intracellular calcium (30). These membrane-initiated steroid 
signaling (MISS) actions are mediated by a pool of intracellular 
receptors localized to caveolae or rafts at the plasma membrane 
(64). The palmitoylation of human ERα cysteine 447 appears to be 
crucial for the targeting of ERα to the plasma membrane through 
physical interaction with caveolin-1 (65, 66). Recently, a mouse 
model where ERα Cys451, the putative palmitoylation site, was 
mutated into alanine has provided the first evidence for a tissue-
specific physiological role of MISS effects of ERα in vivo (67).
These new tools should boost our understanding of the 
ER-dependent signaling mechanisms by which estrogens regulate 
the development and function of DC subpopulations in vivo. In 
vitro studies using mice mutant for AF-1 and AF-2 domains have 
already led to advances in this field (24), but we still lack a detailed 
understanding of the respective contributions of the genomic 
and MISS effects of ERα signaling to DC biology in physiological 
settings in vivo.
DC DeveLOPMeNT AND LiNeAGeS
Murine DCs are generally categorized into three main groups: 
cDCs, pDCs and monocyte-derived inflammatory DCs (moDCs). 
These different populations arise from the common MPs (CMPs) 
found in the bone marrow (21), which become progressively 
restricted into macrophage-DC progenitors (MDPs) (68). 
Although the MDP has been identified as the first progenitor 
committed to the DC and monocyte lineage, the clonal potential 
of MDPs to give rise to both monocytes and DCs is still debated 
(69). Subsequently, a common DC progenitor (CDP), expressing 
high levels of Flt3 has been identified, which gives rise to both the 
cDC and pDC lineages (70).
Conventional DCs
Conventional DCs are subdivided into two main lineages, cDC1 
and cDC2 (19). Conventional cDC1s express the chemokine 
receptor XCR1 (71, 72) and express either CD8α or CD103 (also 
known as αE integrin), but do not express CD11b. The cDC1 
subset is highly efficient at cross-presenting exogenous antigens 
on MHC class I molecules (73–75) and cDC1s further depend 
on a common set of transcription factors (Irf-8, Id2, Nfil3, and 
Batf3) for their development. DCs from the cDC2 subset found 
in the spleen express CD4 and CD172α and cross-present anti-
gens poorly. They are, however, highly competent at presenting 
MHC class II-restricted antigens to CD4+ T cells. In peripheral 
tissues, the homologous subset, CD11b+ DCs (either CD103+ or 
CD103−), do not express CD4 but functionally resemble their 
splenic counterparts (76, 77). CDC2s mainly depend on Irf-4 (78) 
and Relb (79) for their development.
Plasmacytoid DCs
Plasmacytoid DCs are a distinct lineage separated from the cDCs 
by their transcriptional dependency (particularly on E2-2), their 
capacity to secrete abundant type 1 IFN, their morphology, and 
their poor antigen presentation capacity (80–82). They are char-
acterized by their expression of marker molecules B220, Ly49Q, 
Siglec-H, and Bst2 (CD317, bone marrow stromal cell antigen 2, 
also known as PDCA-1) (83) in mouse, and BDCA-2 (CD303) 
and BDCA-4 (CD304) in humans (84).
Monocyte-derived DCs
Monocyte-derived cells were initially considered an important 
reservoir for DC development based on the observation that 
murine and human monocytes can differentiate in  vitro into 
“DC-like” cells in the presence of granulocyte-macrophage 
colony-stimulating factor (GM-CSF, Csf-2) (85, 86). The in vivo 
equivalent of GM-CSF-derived cells has been difficult to identify, 
and it is now clear that they represent a distinct type of highly 
plastic cells able to acquire multiple functions in response to 
environmental cues (87). MCs were initially described as a sub-
set of DCs emerging during inflammation induced by Listeria 
monocytogenes infection and characterized as cells producing 
large amounts of tumor necrosis factor α (TNF-α) and intracel-
lular nitric oxide synthase (iNOS); as such, they were called 
Tip-DC (TNF-α and iNOS-producing DCs) (88). MCs were 
subsequently identified in the response to infection by other 
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pathogens (87, 89) and were shown to differentiate from CCR2+ 
Ly6Chi monocytes recruited to the site of inflammation where 
they can present antigens to both CD4+ and CD8+ T cells (89). 
MCs were shown to be crucial for the induction of Th1 and Th17 
immunity in response to pathogens and following immunization 
in Freund’s complete adjuvant (90, 91). In addition, human MCs 
have been identified in the joints of rheumatoid arthritis patients 
and in tumor ascites and preferentially primed Th17 responses 
(92). Another subset of MCs has been reported to accumulate 
in inflammatory lymph nodes in response to LPS and to express 
CD14 and the c-type lectin DC-SIGN (CD209a) (93). However, 
these cells were subsequently found to express the DC-specific 
transcription factor Zbtb46 (94). Unlike Tip-DCs, LPS-induced 
MCs were lost in Zbtb46-DTR deleter mice treated with diph-
theria toxin and failed to accumulate in Flt3L−/− mice, suggesting 
that these inflammatory DCs were more closely related to the 
cDC lineage (94).
CRiTiCAL ROLe OF e2/eRα-SiGNALiNG 
iN THe GeNeRATiON OF  
CSF-2-iNDUCeD CDCs
Most of the evidence regarding the capacity of estrogens to 
regulate DC development and function has been obtained 
using in  vitro models of DC development, particularly the 
culture of bone marrow cells in the presence of GM-CSF (Csf-
2), a cytokine involved in the development and homeostasis 
of the myeloid lineage (95). It was initially suggested that the 
CD11c+ MHCII+ cells that develop under these conditions were 
equivalent to the inflammatory DCs arising from monocytes 
during inflammation in vivo (96), as mice lacking Csf-2 or its 
receptor do not carry any major defects in the development 
of lymph node and spleen cDCs (21). Csf-2 deficiency has, 
however, been associated with a reduction in the numbers 
of CD103+ cDCs and CD11b+ cDCs in the intestine, dermis, 
and lung (97). Thus, in  vivo Csf-2 appears dispensable for 
lymphoid DC homeostasis, but necessary for the development 
and maintenance of some tissue-resident DCs, suggesting that 
Csf-2 is a critical regulator of cDC survival in non-lymphoid 
tissues (97). Although some studies have suggested that inflam-
matory or mo-DCs can in  vivo develop from progenitor cells 
constitutively lacking Csf-2 receptor (91, 97), evidence also 
exists for a Csf-2-dependent regulation of mo-DC accumula-
tion in tissues during injury and response to pathogens (98). 
For instance, Csf-2 neutralization has been recently reported to 
inhibit the development of a cycling mo-DC population (99). 
On the other hand, CD4+ T cell-derived Csf-2 production can 
drive the generation of mo-DC during inflammatory diseases 
(100, 101) and is essential for the pathogenicity of Th17 cells in 
CNS autoimmunity (102, 103). After subcutaneous immuniza-
tion with antigen in complete Freund’s adjuvant, Csf-2 has been 
reported to promote the differentiation of Th1 or Th17 effector 
cells, by acting on CD103+ dermal DCs (104) or mo-DCs (91), 
respectively. Indeed, Csf-2 is critical for IL-6 and IL-23 produc-
tion by DCs and for Th17 induction in autoimmune myocarditis 
(105) and EAE (91). Thus, besides its potential role in promoting 
the expansion of mo-DCs during inflammation (99–101), Csf-2 
appears also critical in assigning the Th17-inducing potential of 
mo-DCs in vivo (91, 105).
Application of this in vitro model of Csf-2-induced differentia-
tion to either bulk bone marrow cells or highly purified progeni-
tors, such as MDPs, has shown the presence of E2 in the culture 
medium to be critical in promoting the development of CD11c+ 
MHCII+ cells (106) (Table  1). This was initially demonstrated 
by using either steroid-free culture medium supplemented with 
estrogens, pure ER antagonists, or SERMs shown to block ER 
signaling by estrogens originating from fetal calf serum (FCS) 
supplementation (12, 15, 16, 22, 107). These studies concluded 
that estrogens in standard FCS-supplemented medium, probably 
in the 10−10–10−9 M range, are sufficient to promote the develop-
ment of CD11c+ DC-like cells. Such estrogen doses are compat-
ible with physiological concentrations in female mice during 
diestrus and estrus (108). It was then formally established that 
estrogen-mediated activation of ERα, but not ERβ, was necessary 
to promote BMDC development in the presence of Csf-2 (16). 
This was not related to a progenitor deficiency in ERα-deficient 
mice, as the frequency of MDPs and CDPs in the bone marrow 
was not affected (24).
Time-course experiments using the pure ER-antagonist 
ICI182,780 showed that the essential effect of E2 in promoting Csf-
2-mediated DC development occurred within the first 48  h of 
culture (17). This suggested that E2-dependent activation of ERα 
could regulate the activation state or expression level of transcrip-
tion factors implicated in DC lineage commitment in the early 
stages of the differentiation of bone marrow precursors. Indeed, 
it was subsequently reported that E2 acts directly on highly 
purified MPs, including MDPs, to regulate GM-CSF-induced 
differentiation of CD11c+ DC-like cells through the upregulation 
of the transcription factor Irf-4 (15, 17, 24) (Figure 1).
Even though Csf-2 has been widely used to promote the dif-
ferentiation of mouse and human hematopoietic progenitors and 
monocytes into cells resembling mouse splenic DCs (85, 109), it 
was appreciated from the beginning that this culture system har-
bors heterogeneous cell populations. These include monocyte/
macrophage-like cells (85, 109) and CD11chi CD86hi MHCIIhi 
DCs, which arise spontaneously in the absence of exogenous 
danger signals (110). A clarification has been provided recently 
regarding the origin and phenotypic characterization of the cells 
generated in such in vitro model system (111).
Based on their hematopoietic origin and the expression of 
phenotypic markers, it was reported that the CD11c+ MHCII+ 
cells arising in these cultures were comprised of: (i) cMoP-derived 
macrophages (GM-Macs) defined as CD11bhi MHCIIint CD115+, 
and (ii) CDP-derived classical DCs (GM-DCs) expressing high 
levels of MHCII, PDL-2, and Irf-4 and defined as CD115− CD135+ 
cells. The latter subset was enriched in BMDC cultures generated 
with GM-CSF and IL-4, and its development was dependent on 
Irf-4 expression in CD11c+ cells (112). Thus, GM-DCs may be 
more closely related to the CD8α− cDC2 subset, consistent with 
their expression of CD11b and SIRP-α (111).
These results have important implications for the interpreta-
tion of earlier studies on the origin (GM-Macs or GM-DCs) of 
the estrogen-dependent CD11c+ MHCII+ cells that preferentially 
FiGURe 1 | Growth factors and transcription factors regulating conventional dendritic cell (cDC) and plasmacytoid DC (pDC) development.  
A simplified view of the current transcriptional network in DC development is depicted. The plausible developmental stages where E2/ERα-signaling is likely to 
regulate DC development and/or functions are shown. The common DC progenitors (CDPs) that originate from the common progenitor for monocytes and DCs 
[macrophage-DC progenitor (MDP)] produce exclusively the cDC and pDC subsets, but have lost the capacity to generate monocytes. Previous works 
demonstrated that E2 may act directly in MDP to promote interferon regulatory factor (Irf)-4 expression and GM-DC development. Whether E2 may also signal 
through ERα at later stage in CDP to promote cDC2 development still remains to be established. In the pDC lineage, E2 is likely to signal through ERα to promote 
optimal TLR-dependent production of type I interferons (IFNs) through the upregulation of signaling intermediate such as Irf-5, and also possibly through additional 
unknown mechanisms. Solid arrows indicate connections that have been proven, while dotted arrows indicate direct or indirect relationships.
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develop in Csf-2-stimulated bone marrow cultures. In previous 
investigations by different laboratories, the relative expression of 
CD11b and Ly6C among CD11c+ cells was used to better define 
the CD11c+ cell subsets in this model (16, 22), as Ly6C expres-
sion appears to represent a reliable marker of inflammatory 
macrophages, both in vitro and in vivo (21). From initial stud-
ies, it was clear that the CD11bhi Ly6C+ population was mostly 
unchanged by the absence of E2/ERα-signaling. E2, however, 
preferentially promoted the differentiation of CD11c+ CD11bint 
cells lacking Ly6C expression, likely including the GM-DC 
population (16, 22). We corroborated this effect in competition 
experiments using wild-type and ERα-deficient bone marrow 
cells, which provided direct evidence for a cell-autonomous func-
tion of ERα-signaling in promoting the development of CD11c+ 
CD11bint Ly6C− cells. By contrast, the CD11bhi Ly6C+ population 
was reciprocally enriched in estrogen-deprived cultures or in 
the absence of ERα function in the bone marrow precursors. 
This cell population may correspond to the “GM-Macs-like” 
monocyte/macrophage population described by Helft et  al. 
(111). Indeed, we observed a twofold to threefold increase in the 
occurrence of macrophage-like cells in ERα−/− BMDC cultures 
(16). This observation correlated with an increased frequency 
of cells expressing high levels of TLR4-MD2 active complexes 
and CD11b among ERα−/− CD11c+ cells and estrogen-deprived 
wild-type BMDCs (16, 22). Accordingly, these cells produced 
massive amounts of IL-6 and IL-12 upon stimulation with 
LPS, but not in response to TLR9 or CD40 ligands (16, 24). In 
striking contrast, ERα-signaling promoted the development of 
CD11bint Ly6C− CD11c+ cells capable of producing higher levels 
of pro-inflammatory cytokines (IL-16 and IL-12) upon TLR9 
or CD40 activation than ERα−/− CD11c+ cells (16). Moreover, 
ERα−/− DCs, enriched in GM-Macs, were markedly inferior 
at stimulating naive CD4+ T cells, when compared to BMDCs 
from E2-stimulated cultures, when given preprocessed antigenic 
peptides or unprocessed protein antigen (16). Further studies 
are warranted to explain how E2 promotes the development of 
GM-DCs in preference to GM-Macs in this culture model. As 
suggested in Figure  1, E2 could promote GM-DC generation 
by selectively acting in CDPs and/or by regulating the earlier 
transition from MDPs to CDPs.
While canceling estrogen signaling in the GM-CSF culture 
model had no apparent effect on the development of monocyte/
macrophage-like cells, this does not necessarily indicate that 
monocytes or monocyte-derived cells are insensitive to estro-
gen in vivo. In fact, by using the LysM-cre deleter model, we 
provided compelling evidence that ERα signaling in murine 
monocytes/macrophages was associated in  vivo with an 
enhanced production of pro-inflammatory cytokines by peri-
toneal macrophages (8). This ERα-dependent effect of E2 on the 
LPS-driven inflammatory response of macrophages was medi-
ated by inhibition of PI3K activity acting as a negative feedback 
mechanism of TLR4-induced activation (7, 8). This observation 
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is at odds with other studies indicating that in vivo, estrogens 
exert pro-inflammatory actions on murine macrophages and 
microglia (40, 41), whereas ERβ ligands are anti-inflammatory 
(41). This conclusion, however, does not seem to hold for 
human monocytes/macrophages, in light of reports describing 
in  vitro E2-mediated inhibition of LPS-driven production of 
pro-inflammatory cytokines such as IL-6 (113) through the 
blockade of NF-κB signaling (114). Whether this effect involves 
classical ERα is unclear. A recent study showed that the 36-kDa 
isoform of ERα, which excludes the AF-1 and AF-2 domains 
owing to alternative mRNA splicing, was strongly expressed 
in human monocytes and could contribute to the inhibition 
of NF-κB transcriptional activity through direct interaction in 
the nucleus (115). Besides macrophages, the effects of estrogen 
signaling on MCs such as monocyte-derived DCs or TipDCs 
deserve further investigation. Table  1 summarizes known 
ERα-mediated modulatory effects of estrogen on the biological 
responses and functions of DC subsets and monocytes-mac-
rophages in different contexts.
iRF-4 iS A KeY TARGeT OF eRα 
SiGNALiNG iN THe ReGULATiON  
OF DC BiOLOGY
Interferon regulatory factor-4 is a key transcription factor that 
plays an essential role in the regulation of Th2 responses through 
its function in Th2 cells themselves (116, 117) but also in Treg 
cells (118), M2 macrophages (119) and, as shown more recently, 
the cDC2 subset (110, 120). Irf-4 was initially shown to regulate 
the development of CD11bhi CD8α− DCs in the spleen (121), 
though it was unclear whether Irf-4 was required early during 
development, or for continued survival or functional competence 
of Irf-4+ DCs in tissues. Recently, DC-specific deletion of Irf-4 has 
been associated with the absence of CD11b+ CD8α− DCs from 
barrier tissues such as lamina propria, the lung, and the respective 
draining lymph nodes (122, 123). Mice carrying a DC-specific 
deficiency for Irf-4 correctly develop dermal CD11b+ CD301b+ 
PDL2+ DCs in vivo, but these cells fail to localize to the draining 
lymph nodes (110). This is consistent with the known depend-
ency on Irf-4 for DC migration from the skin to the draining 
lymph nodes (124).
Kovats and colleagues identified Irf-4 as a key transcription 
factor whose expression was strongly up-regulated by E2 in 
Csf-2/Stat-5-stimulated MDPs (17). Retrovirally delivered Irf-4 
expression in ERα-/- MDPs restored their potential to develop 
into CD11b+ Ly6C- GM-DCs, indicating that high levels of 
Irf-4 can substitute for the requirement for E2/ERα-signaling 
during Csf-2-mediated DC differentiation (17). Data from our 
laboratory, however, point to further ERα-dependent pathways 
contributing to Csf-2-driven DC development (24). Using mice 
expressing AF-1- or AF-2 domain-defective ERα, we showed 
that both AF domains were required for early Irf-4 expression 
in Csf-2-stimulated MDPs (24). Intriguingly, in spite of the 
absence of Irf-4 upregulation in ERα-AF-10 MDPs, E2 was able 
to sustain GM-DC development and functional responses to 
near-equivalent levels relative to wild-type cells at later time 
points. This observation may explain previous results by oth-
ers showing substantial E2 effects in GM-DC cultures derived 
from the first-generation strain of ERα-mutant mice (12), which 
expressed a truncated form of ERα lacking the AF-1 domain 
(125), similar to the ERαAF-10 mice used in our study (24). 
That AF-1 synergizes with AF-2 to enhance Csf-2-dependent 
expression of Irf-4 in early stage MDPs, but is dispensable at 
later stages of Irf-4-dependent DC development, suggests 
indirect mechanisms of Irf-4 regulation by E2-ERα signaling. 
AF-2 critically controls ERα interactions with most transcrip-
tion cofactors, but AF-1-specific coactivators have also been 
described (126). ERα signaling may regulate Irf-4 through the 
rapid activation of coactivators or corepressors (127), and the 
induction of other transcription factors whose early expression 
may require synergistic interactions between both ERα AFs. 
In the absence of ERα AF1, a longer signaling period could 
be required for alternative pathways of activation or for the 
accumulation of rate-limiting factors above the threshold level 
required to transactivate Irf-4 expression. This would fit in with 
the delayed upregulation of Irf-4 observed in ERαAF-10  MP 
cells as compared to ERα-deficient ones, although many other 
mechanisms could conceivably be at play (24).
ReLevANCe OF e2/eRα SiGNALiNG  
iN CDCs IN VIVO
Little is known regarding the role of ERα-signaling in the 
homeostasis of cDC subsets in lymphoid and non-lymphoid 
tissues in  vivo. Competition experiments in irradiated bone 
marrow chimeras suggested that newly differentiated splenic 
CD11c CD11b+ cDCs arose from ERα-proficient bone marrow 
cells in a ~2:1 ratio to cells derived from the ERα−/− donor (17). 
This model likely represents a pro-inflammatory environment 
where both GM-CSF and Flt3L may be elevated, suggesting that 
ERα-signaling in vivo may promote the development of CD11b+ 
cDC2 subsets. This conclusion, however, needs further confir-
mation as few phenotypic and functional markers were used in 
this study (17).
Experiments by Kovats and colleagues have shown unex-
pectedly that the skin-derived CD103+ cDCs were enriched 
in the cutaneous lymph nodes of female mice as compared to 
males (124). Whether this sex bias was due to estrogens was 
not addressed specifically, but it was independent from Irf-4 
expression, in agreement with the currently accepted notion that 
CD103+ cDCs in the skin belong to the Batf-3-dependent cDC1 
subset. By contrast, the Irf-4-dependent CD11b+ cDC subsets 
showed no such sex bias (124). Thus, despite strong evidence 
that E2-ERα-signaling strongly regulates Irf-4-dependent cDC 
subsets in the in vitro Csf-2 differentiation model, it is still unclear 
how this relates to particular cDC subsets found in lymphoid 
or non-lymphoid tissues in  vivo, at the steady state, or during 
inflammation.
Our search of the ImmGen database at http://www.immgen.
org (128) showed that lung CD11b+ CD103neg DCs display 
the highest levels of Esr1 expression among DC subsets. As 
mentioned above, several studies have shown that a subset 
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of CD11b+ DCs-expressing Irf-4, present in the skin and at 
the mucosal surfaces in the lung and gut, is crucial in driving 
CD4+ T cell responses and effector T cell development (129). 
As ERα-signaling controls the level of Irf-4 in Csf-2-stimulated 
MDPs, and thereby promotes efficient development of the Irf4-
dependent CD11b+ cDC subset in vitro, further investigations 
are warranted on the impact of cell-intrinsic ERα signaling 
in cDCs in  vivo in the context of immune responses against 
allergens or viruses. A sex bias has in fact been reported for res-
piratory pathologies such as allergic asthma and influenza virus 
infection, which are more severe in females than in males (130, 
131). It was also reported recently that E2 treatment increased 
the frequency of Irf-4+ DCs in the murine vaginal mucosa, asso-
ciated with enhanced competence of vaginal DCs to prime Th17 
cells in vitro. It is unresolved whether this effect of E2 hinged on 
ERα signaling in DCs (132).
e2-eRα-SiGNALiNG ReGULATeS THe 
FLT3L-DePeNDeNT DC SUBSeTS, CDCs 
AND PDCs: IN VITRO eviDeNCe
As mentioned earlier, bone marrow progenitors cultured in 
the presence of cytokine Flt3L generate the two main conven-
tional DC subsets (cDC1 and cDC2) as well as pDCs. E2 was 
initially reported to downregulate the development of these 
Flt3L-driven CD11c+ DCs (FL-DCs) through ERα-signaling in 
MPs (15). Later studies used new strains of ERα mutant mice 
that allowed the relative contribution of each AF domain of 
ERα to be examined (24). It was thus shown that this effect of 
E2 depended on the AF-1 domain, but not on AF-2. Precise 
analysis of the DC subsets differentiated in the presence of 
Flt3L confirmed the previous observation that ERα signaling 
negatively regulates the absolute numbers of FL-DCs in vitro. 
This concerned mainly the development of pDCs, whereas 
cDC numbers were largely unchanged (24). Importantly, cDCs 
differentiated in the presence of E2 exhibited an enhanced 
expression of MHC class II and costimulatory molecules, 
and an increased capacity to produce IL-12 and IL-6 upon 
combined stimulation through TLR-4 and CD40. Although E2 
likewise decreased the absolute numbers of pDCs, these cells 
exhibited a more mature phenotype and an enhanced capacity 
to produce the pro-inflammatory cytokine IL-12 in response to 
TLR9 stimulation. Similar to cDCs, these effects of E2 on pDC 
biology were missing in ERα-deficient mice as well as in mice 
defective for the AF-1 function of ERα (24). This requirement 
for AF-1 may point to a dominant role for the genomic actions 
of ERα signaling on target genes, but non-genomic mechanisms 
could also be at play. Studies in mice lacking the MISS function 
of ERα will help to resolve this issue.
Thus, in contrast to the Csf2-model of cDC2 development, 
which is strictly dependent of E2-ERα signaling, the development 
of Flt3L-driven cDCs and pDCs is not abolished in the absence of 
estrogens or Esr1 expression. Instead, our data are consistent with 
a key role of estrogens in promoting the development of cDCs 
and pDCs endowed with a more mature functional phenotype, 
notably characterized by enhanced TLR-mediated responses.
FUNCTiONAL iMPACT OF e2-eRα 
SiGNALiNG ON TLR-DePeNDeNT 
ReSPONSe OF PDCs iN HUMANS
An important issue regards the in vivo relevance of the effects of 
E2 observed in vitro on the development and effector functions of 
cDCs and pDCs, and its translation to human DCs. Addressing 
the hormonal regulation of immune cells in humans is challeng-
ing, and very few studies have as yet been reported. The most 
remarquable observation probably concerns the human pDC 
subsets, whose capacity to produce IFN-α in response to TLR 
ligands has been independently reported to be highly regulated 
by sex-dependent factors (10, 25, 38, 133, 134). Studying large 
cohorts of healthy donors, Berghöfer and colleagues demon-
strated that pDCs in the peripheral blood of women produced 
more type I IFNs in response to TLR7 ligands than pDCs from 
men (133). Subsequent studies showed that this sex bias was in 
fact due to an increased frequency of pDCs capable to secreting 
IFN-α among PBMCs from women, rather than a sex bias in 
IFN-α production on a single cell-basis (10, 134). Support for a 
key role of estrogens in regulating the TLR-mediated response 
of female pDCs came from observations that pDCs from 
postmenopausal women exhibited a reduced TLR7-mediated 
response by comparison with premenopausal women, which 
was partially reversed by hormone replacement therapy with E2 
(10). Indeed, E2-supplementation of postmenopausal women 
was found to substantially enhance IFN-α production by blood 
pDCs not only in response to TLR7 stimulation but also to TLR9 
ligands. Importantly, enhanced cytokine production by pDCs was 
elicited not only by synthetic ligands of TLR7 or TLR9 but also 
by natural ligands such as self nucleic acid-containing immune 
complexes present in the sera of systemic lupus erythematosus 
(SLE) patients (10).
Using an in vitro model of Flt3L/IL-7-driven human pDC dif-
ferentiation from CD34+ HPCs, we showed that blockade of ER 
signaling by the pure ER antagonist ICI182,780 in developing human 
pDCs blunted the IFN-α response to TLR7 ligands (38). Unlike 
their mouse counterparts, however, human pDCs expressed both 
ER genes, ESR1 and ESR2 (38). It will, therefore, be of impor-
tance to investigate the respective contributions of ERα and ERβ 
to the TLR7-dependent response of human pDCs. The role of 
either receptor is complex and often mutually antagonistic when 
expressed in the same cells (135).
MeCHANiSMS OF eRα-MeDiATeD 
ReGULATiON OF TYPe i iFNs iN PDCs
Because they target virtually any cell type in the organism, 
understanding the mechanisms of immune cell regulation by 
estrogens is often not straightforward. New mouse models have 
been generated recently to induce conditional deletions of ER in 
order to discriminate between direct and indirect in vivo effects of 
estrogens on DC functions (8–10). Using such models, the impact 
of ER deficiency in specific immune cell types in the context of 
physiological hormone levels has been assessed (8, 10, 25). These 
studies pinpointing the cellular targets of estrogens are critical 
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to understanding the molecular mechanisms of ER-regulated 
immune responses in vivo.
Using mice lacking ERα in CD11c-expressing cells specifically, 
it was established that ERα expression in pDCs was required for 
the estrogen-mediated increase of IFN-α (10, 25). This in  vivo 
cell-intrinsic modulation by estrogen of the TLR7- and TLR9-
dependent responses in mouse pDCs (10, 25) was corroborated 
by evidence from in  vitro models of murine and human pDC 
development (24, 38). Altogether, these studies provided new 
insights into the mechanism of sex bias in the TLR-driven IFN-α 
production of female pDCs and identified ERα as an attractive 
target for specific modulation of this pathway.
Interferon-α induction is regulated primarily at the transcrip-
tional level by members of the interferon regulatory factor (Irf) 
family (136). Human pDCs constitutively express high levels 
of Irf-5 and Irf-7, and TLR9 engagement in pDCs leads to the 
activation and phosphorylation of both Irf-5 and Irf-7 (20). Irf-7 
is widely recognized as the “master regulator” of type I IFN pro-
duction (137), while Irf-5 has been shown to be a central media-
tor of TLR7 signaling in mice (138, 139). In human pDCs, the 
production of IFN-α through TLR7 or TLR9 stimulation relies on 
PI3K activities and the phosphorylation of Akt, leading to nuclear 
translocation of Irf-7 (140). However, a recent study in human 
pDC leukemic cells challenged the notion of a key regulatory role 
of Irf-7 in type I IFN production by human pDCs. It was reported 
that Irf-5, rather than Irf-7, played a non-redundant role in IFN-β 
and IL-6 production following cell stimulation with TLR9 ligands 
(36). Thus, while Irf-7 is the master regulator of type I IFN pro-
duction upon TLR7 or TLR9 stimulation in mouse pDCs, the 
respective contribution of Irf-7 and Irf-5 to IFN-α induction in 
human cells is yet to be clarified.
The role of Irf-5 in the differential IFN-α production between 
females and males was investigated recently (25). Basal levels of 
Irf-5 were significantly higher in the pDCs from women and 
positively correlated with the frequency of IFN-α-secreting 
pDCs upon TLR7 stimulation. Genetic ablation of the Esr1 gene 
in the hematopoietic compartment or the DC lineage of female 
mice reduced Irf-5 mRNA expression in pDCs and IFN-α pro-
duction upon stimulation with TLR7 ligand-containing vesicles. 
Of note, Irf-7 expression in bone marrow pDCs was not affected 
by ERα deficiency (25). These results suggest that estrogens 
regulate pDC type I IFN production through Irf-5, which may 
act by enhancing IFN-α production in synergy with Irf-7 (141). 
This would be particularly relevant to human pDCs, whose 
capacity to produce IFN-β upon TLR9 engagement has been 
shown to depend strongly on Irf-5, rather than on Irf-7 (36, 141). 
However, a direct relationship between E2-ERα signaling and 
Irf-5 expression has yet to be established. In parallel, it has been 
reported that estrogen signaling in immune cells upregulated 
the expression of the endoplasmic reticulum transmembrane 
protein Unc93b1 (142). This chaperone molecule regulates the 
trafficking of TLR3, TLR7, and TLR9 from the endoplasmic 
reticulum to the endosomal compartments, and Unc93b1 
knockdown abrogates cytokine production (143). However, 
estrogen-mediated regulation of Unc93b1 was not assessed in 
pDCs, and it was unclear whether this regulation involved cell-
intrinsic ERα signaling (142). The contribution of Unc93b1 to 
the sex-bias in the TLR-mediated response of pDCs remains an 
unsettled question.
While a study has suggested a direct regulation of TLR expres-
sion through ERα signaling in human monocyte-derived mac-
rophages (144), we and others have failed to detect sex-dependent 
modulation of TLR7 or TLR9 gene expression in pDCs, at least at 
the mRNA level in bulk cell populations (38, 133). Confirmation 
of these results in various TLR7-expressing cells both in mice and 
human will be necessary, along with analyses of protein expres-
sion levels using highly specific antibodies.
Other than TLRs and proteins implicated in their intracellular 
trafficking, a recent study pointed to ERα-dependent regulation 
of the cell surface molecule PDC-triggering receptor expressed 
on myeloid cells (TREM) in pDCs from lupus-prone mice. 
PDC-TREM is a pDC-specific receptor, a member of the TREM 
family, which is induced by TLR signaling and mediates IFN-α 
production (145). ERα deficiency reduced the TLR9-dependent 
expression of PDC-TREM in pDCs from mice of NZM2410 
(lupus-prone) or C57BL/6 genetic background (146). Although 
PDC-TREM expression is reportedly required for optimal pro-
duction of type I IFNs by TLR9-stimulated pDCs (145), further 
studies are needed for any functional links to be established 
between ERα-dependent regulation of PDC-TREM and changes 
in the TLR-responsiveness of pDCs.
Despite recent inroads, the mechanistic details of the functional 
impact of E2-ERα signaling on the TLR-dependent responses of 
pDCs remain largely unexplored. Apart from the direct regula-
tion of genes implicated in the TLR signaling pathway, ERα could 
control the expression of key pDC transcription factors, such as 
E2-2, Spi-B, Irf-8, Irf-7, and Ikaros. One would also expect major 
effects on the development of pDCs in the bone marrow. This 
raises exciting questions for investigators, because understanding 
the mechanisms that promote pDC development and regulate 
their peripheral function will be key to manipulating this cellular 
compartment through ER signaling to enforce homeostasis and 
fight chronic inflammation. The sexual dimorphism in type I IFN 
production by pDCs could indeed be implicated in the increased 
susceptibility of women to autoimmunity, and in the sex differ-
ences vis-à-vis the acquisition and clinical course of certain viral 
diseases (1).
CONCLUDiNG ReMARKS
Evidence is emerging that estrogens, through their nuclear recep-
tor ERα, regulate various facets of cDC and pDC develoment and 
TLR-dependent responses in humans and mice. However, the 
full demonstration of a direct involvement of this pathway in the 
sex-biased susceptibility to autoimmunity or infection remains 
a work in progress. Genetic and cell type-specific Esr1 deletion 
strategies have come to the fore as critical tools, and further 
investigations regarding genes regulated by estrogens in DCs are 
eagerly awaited. Such unbiased approaches should shed light on 
the molecular mechanisms set in motion by cell-intrinsic E2-ERα 
signaling in DCs in the physiological context of the female 
environment. Another important issue concerns the optimal 
experimental models to study the role of sex hormones. Although 
standard estrogen supplementation is useful in addressing certain 
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questions, it does not mirror the estrus cycle and, because of the 
pleiotropic actions of sexual hormones, may introduce confound-
ing factors, especially in integrated models of autoimmune or 
infectious diseases. The physiological context of natural estrogen 
production during the estrus cycle should, therefore, be preferred 
over experimental models of E2-supplementation, as the only 
natural instance of sustained steroid hormone production is 
pregnancy.
The pDC subset appears to be subjected to estrogen-dependent 
regulation, notably in regard of its functional capacity to produce 
type I IFNs in response to TLR7 ligands (133, 134). Evidence has 
arisen that E2-ERα signaling and X-linked genetic factors inde-
pendently contribute to the strong sex bias in the TLR7-driven 
response of pDCs (10, 38). Cell type-specific strategies of genetic 
ablation have recently demonstrated the pivotal role of pDCs 
in the development of autoantibodies and in the progression of 
lupus-like syndrome (147, 148). Targeting the ER signaling path-
way in pDCs could represent a valuable therapeutic approach to 
limit the pathogenic production of type I IFN, particularly during 
the initial stages of SLE. Indeed, early studies suggested beneficial 
effects of RE antagonists or SERMs in mouse models of lupus 
(149, 150). Encouraging results were reported from a clinical 
double-blind trial of fulvestrant (ICI182,780) in women with SLE 
(151). In patients treated for 12 months, an improvement in clini-
cal signs was observed, associated with a reduction of medication 
dosage (151). Together with our in vitro results showing ICI182,780 
to downregulate the TLR7-type I IFN pathway in developing 
human pDCs, these clinical outcomes strongly suggest that ER 
signaling could be amenable to pharmacological manipulation in 
pDCs. Along this line, we reported earlier that E2 supplementa-
tion in postmenopausal women enhances the TLR7- and TLR9-
dependent production of type I IFNs (10).
In addition to the well-established sex bias in the incidence 
and severity of autoimmune diseases, sex differences in the 
response to viral vaccines have been also clearly documented 
in humans and in mice (130, 152). Given the central role of 
DCs in the initiation of adaptive immunity, studying how sex-
related factors could regulate the homeostasis and responses of 
tissue-resident DC subsets at steady state and in the context of 
vaccination using attenuated viruses or vaccine sub-units is of 
critical importance. For instance, prophylactic vaccination with 
HSV-2 glycoprotein D in adjuvant exhibited efficacy in women, 
but not in men (153). More recently, systems biology approaches 
have shown that expression of genes associated with TLR and IFN 
pathways immediately after vaccination with yellow fever virus 
17D predicted subsequent adaptive immune responses (154, 155). 
Interestingly, re-analysis of these data according to the sex of the 
subjects demonstrated that most of the TLR-associated genes that 
activate the IFN pathway were upregulated to a greater extent in 
women as compared to men during the first 10 days after vac-
cination (130). Although this may suggest that disease protection 
might be greater in women than in men, this also indicates that 
the enhanced innate immune response to YF17FD vaccine might 
also underlie the increased incidence of side-effects in women 
(130). These examples illustrate the importance of understand-
ing how sex-linked factors could contribute to regulate innate 
immunity, and particularly DC biology. This may help to explain 
and predict the heterogeneous responses to vaccines in humans 
according to sex, not only in the context of infectious diseases but 
also in cancer immunotherapy.
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